This document summarizes a journal club discussion of a randomized trial comparing outcomes of intracranial pressure monitoring versus clinical examination alone for patients with severe traumatic brain injury. Key points included that the trial found similar outcomes between the two groups in composite endpoints and mortality. However, the intracranial pressure monitoring group received more aggressive treatments such as barbiturates. There was skepticism around applying the results to clinical practice in the US due to differences in pre-hospital care, rehabilitation standards, and treatment protocols between the study locations and the US.
Trial of decompressive craniectomy for traumatic intracranial hypertension1Dr fakhir Raza
油
The New England Journal of Medicine, Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension, Extended Glasgow Outcome Scale (GOS-E), vegetative state, lower severe disability, traumatic brain injury, RESCUEicp,
Effect of hydrocortisone on development of shock amongDr fakhir Raza
油
effects of hydrocortisone on development of shock among patients with severe sepsis the HYPRESS Randomized Clinical Trial American Medical Association caring for the critically ill patients Surviving sepsis campaign, to determine weather hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock
This document summarizes the results of the NOR-TEST trial, which compared the intravenous thrombolytics tenecteplase and alteplase for the treatment of acute ischemic stroke. The trial found that tenecteplase was not superior to alteplase in achieving excellent functional outcomes or in rates of intracranial hemorrhage. Both intention-to-treat and per-protocol analyses showed similar efficacy and safety profiles between the two drugs. While tenecteplase has theoretical advantages, this large phase 3 trial did not demonstrate it to be clearly better than the current standard treatment of alteplase.
The DANISH trial investigated whether implanting an ICD in patients with non-ischemic heart failure reduced mortality. Over 67 months of follow-up:
1) ICD implantation did not provide an overall survival benefit compared to usual care.
2) The risk of sudden cardiac death was halved with an ICD.
3) Younger patients and those receiving CRT may benefit more from an ICD.
4) ICDs were associated with device-related complications but reduced inappropriate shocks compared to earlier studies. The trial adds to understanding ICD benefits in non-ischemic heart failure.
This clinical study examined whether decompressive craniectomy (DC) reduces cumulative ischemic burden and therapeutic intensity levels in severe traumatic brain injury (TBI) patients with elevated intracranial pressure (ICP). The study found that performing DC on 10 severe TBI patients with elevated ICP reduced ICP immediately and lowered therapeutic intensity levels within 12 hours after surgery. DC also significantly reduced the duration and severity of cumulative ischemic burden in these patients. Overall mortality was lower than predicted, suggesting DC may help reduce secondary brain injury from elevated ICP in severe TBI.
Trial 1 examined the effect of intensive lipid-lowering therapy to achieve an LDL cholesterol level below 70 mg/dL compared to a target range of 90-110 mg/dL in patients with atherosclerotic disease at risk for cardiovascular events. The study found that intensive therapy reduced the risk of cardiovascular events with a hazard ratio of 0.78.
Trial 2 analyzed CSF biomarkers to differentiate idiopathic normal pressure hydrocephalus (iNPH) from other cognitive and movement disorders. The study found that a profile of low levels of tau and A硫40 and high levels of MCP-1 in CSF increased the probability of iNPH compared to other disorders such as Alzheimer's disease and Parkinson's disease. Combin
This document discusses hypothermia as a potential treatment for traumatic brain injury (TBI). It provides an overview of the mechanisms by which hypothermia may be neuroprotective after TBI. It then reviews the results of numerous clinical trials that have investigated hypothermia for TBI, finding no clear evidence of improved outcomes with hypothermia compared to normothermia. The document concludes by discussing reasons for the lack of evidence and considerations for future trials, as the role of hypothermia in TBI remains uncertain.
SURVEY OF TURKISH PRACTICE EVALUATING THE MANAGEMENT OF POSTDURAL PUNCTURE HE...MedicineAndHealth
油
This survey examined practices for managing postdural puncture headache (PDPH) in obstetric patients in Turkey. 78 responses were received from anesthesiologists. For accidental dural puncture during labor epidurals, re-siting the epidural at a different level or leaving the catheter in place as a spinal was preferred to prevent PDPH. Conservative treatments like fluids, pain medications, and caffeine were commonly used initially for PDPH. An epidural blood patch was the preferred next step if conservative treatments failed and was generally performed within 24 hours with monitoring and bed rest afterwards. While practices varied, the survey highlighted current Turkish approaches to PDPH prevention and management in obstetrics. Further surveys were
This document summarizes research on intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury. It discusses several key points:
1. While ICP monitoring is commonly recommended, the evidence from randomized controlled trials does not clearly support its use. One trial found no benefit to management guided by ICP monitoring over clinical exams and CT scans.
2. Guidelines set ICP thresholds for intervention but the optimal thresholds are unclear. Some studies found thresholds of 22 mmHg for mortality and functional outcomes.
3. Monitoring cerebral perfusion pressure (CPP) in addition to ICP may be important as outcomes improved with better adherence to CPP guidelines over time.
4. Effective treatments for elevated
This research article compares the safety, efficacy, and cost-effectiveness of primary percutaneous coronary intervention (PCI) versus a pharmaco-invasive strategy for ST-segment elevation myocardial infarction (STEMI) patients in Gaza. 145 patients were randomized to primary PCI or streptokinase fibrinolysis followed by rescue or routine PCI within 2-24 hours. The primary composite endpoint of death, shock, or heart failure at 30 days was similar between groups. However, the pharmaco-invasive strategy had higher rates of major bleeding and required emergency angiography in 39.5% of patients. While index hospitalization costs were lower, the total estimated 30-day cost per 100 patients was higher for the pharmaco-invasive strategy compared
This document discusses decompressive craniectomy for refractory intracranial hypertension. It provides rationale and indications for decompressive craniectomy, which aims to reduce intracranial pressure by removing part of the skull. Common complications are also mentioned. Guidelines from the American Association of Neurological Surgeons are presented regarding criteria for performing decompressive craniectomy in patients with traumatic brain injury or refractory increased intracranial pressure. Outcomes of decompressive craniectomy are discussed for different patient groups.
Dexamethasone trial in chronic subdural hematomaSandesh Dahal
油
This document summarizes a journal club presentation on a randomized controlled trial investigating the use of dexamethasone for chronic subdural hematoma. The trial found that patients receiving dexamethasone had a less favorable functional outcome at 6 months compared to placebo, as measured by the modified Rankin scale. Secondary outcomes also showed higher rates of adverse events in the dexamethasone group. The results do not support the use of dexamethasone for chronic subdural hematoma as it may be associated with harm.
Tenecteplase may be a better fibrinolytic than alteplase for treating acute ischemic stroke with complete vessel occlusion. A pooled analysis of 146 patients from two studies found that patients receiving tenecteplase had higher recanalization rates at 24 hours, better 24-hour NIHSS scores, and improved 90-day outcomes as measured by the mRS scale compared to alteplase, with less symptomatic intracerebral hemorrhage. However, the studies were small and open-label, so larger randomized controlled trials are still needed to definitively determine if tenecteplase provides superior clinical benefits over alteplase.
Endovascular thrombectomy plus standard medical care improved outcomes for patients with acute stroke compared to standard care alone when performed 6 to 24 hours after the patient was last known to be well. The DAWN trial showed that for patients with a clinical deficit disproportionate to the size of their brain infarction based on imaging, thrombectomy led to better disability and functional independence outcomes at 90 days. Benefit was seen across subgroups based on age, stroke severity, occlusion site, and time from onset. This expands the treatment window for thrombectomy beyond the typical 6 hours.
This document summarizes the results of the ENCHANTED clinical trial which compared low-dose (0.6 mg/kg) intravenous alteplase to standard-dose (0.9 mg/kg) for acute ischemic stroke. The trial found that low-dose alteplase was not inferior to standard-dose for functional outcomes at 90 days, carried a lower risk of symptomatic intracerebral hemorrhage, and showed a trend toward lower mortality. Specifically, major hemorrhage occurred in 1.0% of low-dose patients versus 2.1% of standard-dose patients. Mortality was also lower in the low-dose group at 7 days. The study demonstrates that a lower dose of
1) The VISSIT trial compared outcomes of 112 patients with symptomatic intracranial stenosis randomized to balloon-expandable stent plus medical therapy or medical therapy alone. At 1 year, the stent group had a higher risk of stroke or TIA compared to the medical therapy group.
2) The CADISS trial randomized 250 patients with carotid or vertebral artery dissection to antiplatelet drugs or anticoagulant drugs for 3 months. Both groups had low risks of stroke, with no significant difference between treatments.
3) The ATTEST trial compared tenecteplase to alteplase in 104 patients with acute ischemic stroke within 4.5 hours of onset. There were no significant differences in pen
Hospital Medicine Update, VA ACP Meeting 2015Jon Sweet
油
This document summarizes a presentation on papers that have changed the presenter's medical practice. It discusses several clinical cases and the evidence from recent studies on how to best manage them. For a patient with upper GI bleeding admitted after endoscopic treatment, intermittent PPI therapy is shown to be non-inferior to continuous infusion PPI based on multiple randomized trials. For heart failure patients under 75, BNP-guided treatment reduces mortality and hospitalizations compared to clinical guidance alone. Lower steroid doses are associated with better outcomes for COPD patients admitted to the ICU. MRCP or EUS are recommended for evaluating the CBD in patients at intermediate risk of retained stones.
1) The document discusses the principles and evidence for early management of spinal cord injuries, including early surgery within 24 hours, maintaining mean arterial blood pressure between 85-90 mmHg, and the use of methylprednisolone.
2) Ongoing clinical trials are exploring optimal perfusion pressure targets as well as neuroprotective agents like riluzole.
3) Specialized spinal cord injury units allow for up-to-date management and access to clinical trials exploring new treatments.
Thrombectomy in Stroke: DAWN and DEFUSE3 trial dataSCGH ED CME
油
The document summarizes key findings from several recent clinical trials evaluating endovascular thrombectomy for acute ischemic stroke:
1. The HERMES meta-analysis of 5 randomized controlled trials from 2010-2015 found endovascular thrombectomy plus standard care significantly reduced disability at 90 days compared to standard care alone.
2. The DEFUSE3 trial of 182 patients found endovascular therapy plus medical therapy improved functional outcomes and reduced mortality compared to medical therapy alone for strokes 6-16 hours.
3. The DAWN trial of 206 patients found the same benefits for strokes 6-24 hours when a clinical-radiological mismatch was present. Both DEFUSE3 and DAWN saw no increase in serious adverse events.
This study compared outcomes of early mobilization (out of bed after 52 hours) versus delayed mobilization (out of bed after 7 days) in 50 patients with ischemic stroke. There were fewer severe complications in the early mobilization group (2 patients, 8%) compared to the delayed group (8 patients, 47%). However, there were no differences in total complications or 3-month clinical outcomes between the groups. Cerebral blood flow measurements also did not differ between groups. The results suggest early mobilization reduces severe complications without increasing risk and supports larger trials to further evaluate optimal mobilization timing.
This document summarizes a study on the effects of intraoperative mild hypothermia in patients undergoing neurosurgery for subarachnoid hemorrhage. The study was a prospective randomized controlled trial including 1001 patients from 30 centers. Patients were randomly assigned to receive either intraoperative hypothermia at 33属C or normothermia at 36.5属C. The study found that mild hypothermia provided no overall benefit to patient outcomes at 90 days post-surgery compared to normothermia. However, a subgroup analysis found hypothermia may be beneficial for patients undergoing surgery 8-14 days after hemorrhage or for male patients, but these effects were lost after adjusting for other factors.
This randomized controlled trial investigated whether acupuncture or sham acupuncture was more effective than no acupuncture in reducing migraine headaches in 302 patients. The trial found that both acupuncture and sham acupuncture led to greater reductions in moderate or severe headache days compared to the waiting list control group. However, acupuncture was not found to be more effective than sham acupuncture for reducing headache days. The proportion of "responders", defined as at least a 50% reduction in headache days, was similar between the acupuncture (51%) and sham acupuncture (53%) groups, and higher than the waiting list group (15%). The trial concluded that acupuncture was no more effective than sham acupuncture for reducing migraine headaches, although both were more
This study reviewed 7 previous studies to investigate whether a 90 minute door-to-balloon time (DTB) metric improves outcomes for STEMI patients undergoing percutaneous coronary intervention (PCI). The results of the studies were mixed, with some showing decreased mortality for shorter DTB times below 2 hours, while others found no significant change in mortality even as DTB times decreased. The authors concluded that while DTB is important and any treatment delay can increase mortality, it is not the sole determining factor and total ischemic time must also be considered. Efforts to improve outcomes should focus on decreasing time from symptom onset to hospital presentation as well as time to treatment.
Update on cardiac arrrest and post cardiac arrest management16 1-18Anand Tiwari
油
This document summarizes updates on cardiac arrest and post-cardiac arrest management. It discusses key changes including emphasizing high-quality CPR, early defibrillation, and targeted temperature management. Intubation is now de-emphasized as it can interrupt chest compressions and be associated with lower survival rates. Post-cardiac arrest care focuses on coronary angiography for suspected cardiac causes and targeted temperature management at 32-36属C for at least 24 hours. Multiple clinical exams, tests and biomarkers can help predict neurological outcomes but should be used together given limitations of individual methods.
The document summarizes guidelines from the Brain Trauma Foundation (BTF) for the management of severe traumatic brain injury (TBI). The BTF released the 4th edition of these guidelines in 2016 to provide evidence-based recommendations for treating severe TBIs. The guidelines provide recommendations on various treatment strategies, such as decompressive craniectomy, hypothermia, hyperosmolar therapy, cerebrospinal fluid drainage, ventilation, anesthetics/sedatives, and monitoring thresholds. Each recommendation is assigned a level depending on the quality of evidence.
This document summarizes evaluation and management of elevated intracranial pressure in adults. It discusses causes of increased intracranial pressure including brain masses, edema, hydrocephalus, and venous obstruction. It covers monitoring of intracranial pressure, indications for monitoring, and types of monitors. It also provides an overview of general management strategies and specific therapies to lower intracranial pressure such as osmotic therapy, glucocorticoids, hyperventilation, barbiturates, and decompressive craniectomy.
Lessons from the TTM trial and planning for the nexstscanFOAM
油
1) Detailed neurological examinations and blinded prognostication were conducted in the TTM trials to minimize bias in outcomes.
2) Follow-up assessments at 6 months in TTM1 found cognitive impairment, depression, and reduced quality of life in about one third of patients despite similar mortality between groups.
3) Extended cognitive testing in TTM1 at 6 months revealed memory, executive function, and processing speed impairments in about half of patients, more than in risk-factor matched controls, showing long-term cognitive consequences after cardiac arrest.
SURVEY OF TURKISH PRACTICE EVALUATING THE MANAGEMENT OF POSTDURAL PUNCTURE HE...MedicineAndHealth
油
This survey examined practices for managing postdural puncture headache (PDPH) in obstetric patients in Turkey. 78 responses were received from anesthesiologists. For accidental dural puncture during labor epidurals, re-siting the epidural at a different level or leaving the catheter in place as a spinal was preferred to prevent PDPH. Conservative treatments like fluids, pain medications, and caffeine were commonly used initially for PDPH. An epidural blood patch was the preferred next step if conservative treatments failed and was generally performed within 24 hours with monitoring and bed rest afterwards. While practices varied, the survey highlighted current Turkish approaches to PDPH prevention and management in obstetrics. Further surveys were
This document summarizes research on intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury. It discusses several key points:
1. While ICP monitoring is commonly recommended, the evidence from randomized controlled trials does not clearly support its use. One trial found no benefit to management guided by ICP monitoring over clinical exams and CT scans.
2. Guidelines set ICP thresholds for intervention but the optimal thresholds are unclear. Some studies found thresholds of 22 mmHg for mortality and functional outcomes.
3. Monitoring cerebral perfusion pressure (CPP) in addition to ICP may be important as outcomes improved with better adherence to CPP guidelines over time.
4. Effective treatments for elevated
This research article compares the safety, efficacy, and cost-effectiveness of primary percutaneous coronary intervention (PCI) versus a pharmaco-invasive strategy for ST-segment elevation myocardial infarction (STEMI) patients in Gaza. 145 patients were randomized to primary PCI or streptokinase fibrinolysis followed by rescue or routine PCI within 2-24 hours. The primary composite endpoint of death, shock, or heart failure at 30 days was similar between groups. However, the pharmaco-invasive strategy had higher rates of major bleeding and required emergency angiography in 39.5% of patients. While index hospitalization costs were lower, the total estimated 30-day cost per 100 patients was higher for the pharmaco-invasive strategy compared
This document discusses decompressive craniectomy for refractory intracranial hypertension. It provides rationale and indications for decompressive craniectomy, which aims to reduce intracranial pressure by removing part of the skull. Common complications are also mentioned. Guidelines from the American Association of Neurological Surgeons are presented regarding criteria for performing decompressive craniectomy in patients with traumatic brain injury or refractory increased intracranial pressure. Outcomes of decompressive craniectomy are discussed for different patient groups.
Dexamethasone trial in chronic subdural hematomaSandesh Dahal
油
This document summarizes a journal club presentation on a randomized controlled trial investigating the use of dexamethasone for chronic subdural hematoma. The trial found that patients receiving dexamethasone had a less favorable functional outcome at 6 months compared to placebo, as measured by the modified Rankin scale. Secondary outcomes also showed higher rates of adverse events in the dexamethasone group. The results do not support the use of dexamethasone for chronic subdural hematoma as it may be associated with harm.
Tenecteplase may be a better fibrinolytic than alteplase for treating acute ischemic stroke with complete vessel occlusion. A pooled analysis of 146 patients from two studies found that patients receiving tenecteplase had higher recanalization rates at 24 hours, better 24-hour NIHSS scores, and improved 90-day outcomes as measured by the mRS scale compared to alteplase, with less symptomatic intracerebral hemorrhage. However, the studies were small and open-label, so larger randomized controlled trials are still needed to definitively determine if tenecteplase provides superior clinical benefits over alteplase.
Endovascular thrombectomy plus standard medical care improved outcomes for patients with acute stroke compared to standard care alone when performed 6 to 24 hours after the patient was last known to be well. The DAWN trial showed that for patients with a clinical deficit disproportionate to the size of their brain infarction based on imaging, thrombectomy led to better disability and functional independence outcomes at 90 days. Benefit was seen across subgroups based on age, stroke severity, occlusion site, and time from onset. This expands the treatment window for thrombectomy beyond the typical 6 hours.
This document summarizes the results of the ENCHANTED clinical trial which compared low-dose (0.6 mg/kg) intravenous alteplase to standard-dose (0.9 mg/kg) for acute ischemic stroke. The trial found that low-dose alteplase was not inferior to standard-dose for functional outcomes at 90 days, carried a lower risk of symptomatic intracerebral hemorrhage, and showed a trend toward lower mortality. Specifically, major hemorrhage occurred in 1.0% of low-dose patients versus 2.1% of standard-dose patients. Mortality was also lower in the low-dose group at 7 days. The study demonstrates that a lower dose of
1) The VISSIT trial compared outcomes of 112 patients with symptomatic intracranial stenosis randomized to balloon-expandable stent plus medical therapy or medical therapy alone. At 1 year, the stent group had a higher risk of stroke or TIA compared to the medical therapy group.
2) The CADISS trial randomized 250 patients with carotid or vertebral artery dissection to antiplatelet drugs or anticoagulant drugs for 3 months. Both groups had low risks of stroke, with no significant difference between treatments.
3) The ATTEST trial compared tenecteplase to alteplase in 104 patients with acute ischemic stroke within 4.5 hours of onset. There were no significant differences in pen
Hospital Medicine Update, VA ACP Meeting 2015Jon Sweet
油
This document summarizes a presentation on papers that have changed the presenter's medical practice. It discusses several clinical cases and the evidence from recent studies on how to best manage them. For a patient with upper GI bleeding admitted after endoscopic treatment, intermittent PPI therapy is shown to be non-inferior to continuous infusion PPI based on multiple randomized trials. For heart failure patients under 75, BNP-guided treatment reduces mortality and hospitalizations compared to clinical guidance alone. Lower steroid doses are associated with better outcomes for COPD patients admitted to the ICU. MRCP or EUS are recommended for evaluating the CBD in patients at intermediate risk of retained stones.
1) The document discusses the principles and evidence for early management of spinal cord injuries, including early surgery within 24 hours, maintaining mean arterial blood pressure between 85-90 mmHg, and the use of methylprednisolone.
2) Ongoing clinical trials are exploring optimal perfusion pressure targets as well as neuroprotective agents like riluzole.
3) Specialized spinal cord injury units allow for up-to-date management and access to clinical trials exploring new treatments.
Thrombectomy in Stroke: DAWN and DEFUSE3 trial dataSCGH ED CME
油
The document summarizes key findings from several recent clinical trials evaluating endovascular thrombectomy for acute ischemic stroke:
1. The HERMES meta-analysis of 5 randomized controlled trials from 2010-2015 found endovascular thrombectomy plus standard care significantly reduced disability at 90 days compared to standard care alone.
2. The DEFUSE3 trial of 182 patients found endovascular therapy plus medical therapy improved functional outcomes and reduced mortality compared to medical therapy alone for strokes 6-16 hours.
3. The DAWN trial of 206 patients found the same benefits for strokes 6-24 hours when a clinical-radiological mismatch was present. Both DEFUSE3 and DAWN saw no increase in serious adverse events.
This study compared outcomes of early mobilization (out of bed after 52 hours) versus delayed mobilization (out of bed after 7 days) in 50 patients with ischemic stroke. There were fewer severe complications in the early mobilization group (2 patients, 8%) compared to the delayed group (8 patients, 47%). However, there were no differences in total complications or 3-month clinical outcomes between the groups. Cerebral blood flow measurements also did not differ between groups. The results suggest early mobilization reduces severe complications without increasing risk and supports larger trials to further evaluate optimal mobilization timing.
This document summarizes a study on the effects of intraoperative mild hypothermia in patients undergoing neurosurgery for subarachnoid hemorrhage. The study was a prospective randomized controlled trial including 1001 patients from 30 centers. Patients were randomly assigned to receive either intraoperative hypothermia at 33属C or normothermia at 36.5属C. The study found that mild hypothermia provided no overall benefit to patient outcomes at 90 days post-surgery compared to normothermia. However, a subgroup analysis found hypothermia may be beneficial for patients undergoing surgery 8-14 days after hemorrhage or for male patients, but these effects were lost after adjusting for other factors.
This randomized controlled trial investigated whether acupuncture or sham acupuncture was more effective than no acupuncture in reducing migraine headaches in 302 patients. The trial found that both acupuncture and sham acupuncture led to greater reductions in moderate or severe headache days compared to the waiting list control group. However, acupuncture was not found to be more effective than sham acupuncture for reducing headache days. The proportion of "responders", defined as at least a 50% reduction in headache days, was similar between the acupuncture (51%) and sham acupuncture (53%) groups, and higher than the waiting list group (15%). The trial concluded that acupuncture was no more effective than sham acupuncture for reducing migraine headaches, although both were more
This study reviewed 7 previous studies to investigate whether a 90 minute door-to-balloon time (DTB) metric improves outcomes for STEMI patients undergoing percutaneous coronary intervention (PCI). The results of the studies were mixed, with some showing decreased mortality for shorter DTB times below 2 hours, while others found no significant change in mortality even as DTB times decreased. The authors concluded that while DTB is important and any treatment delay can increase mortality, it is not the sole determining factor and total ischemic time must also be considered. Efforts to improve outcomes should focus on decreasing time from symptom onset to hospital presentation as well as time to treatment.
Update on cardiac arrrest and post cardiac arrest management16 1-18Anand Tiwari
油
This document summarizes updates on cardiac arrest and post-cardiac arrest management. It discusses key changes including emphasizing high-quality CPR, early defibrillation, and targeted temperature management. Intubation is now de-emphasized as it can interrupt chest compressions and be associated with lower survival rates. Post-cardiac arrest care focuses on coronary angiography for suspected cardiac causes and targeted temperature management at 32-36属C for at least 24 hours. Multiple clinical exams, tests and biomarkers can help predict neurological outcomes but should be used together given limitations of individual methods.
The document summarizes guidelines from the Brain Trauma Foundation (BTF) for the management of severe traumatic brain injury (TBI). The BTF released the 4th edition of these guidelines in 2016 to provide evidence-based recommendations for treating severe TBIs. The guidelines provide recommendations on various treatment strategies, such as decompressive craniectomy, hypothermia, hyperosmolar therapy, cerebrospinal fluid drainage, ventilation, anesthetics/sedatives, and monitoring thresholds. Each recommendation is assigned a level depending on the quality of evidence.
This document summarizes evaluation and management of elevated intracranial pressure in adults. It discusses causes of increased intracranial pressure including brain masses, edema, hydrocephalus, and venous obstruction. It covers monitoring of intracranial pressure, indications for monitoring, and types of monitors. It also provides an overview of general management strategies and specific therapies to lower intracranial pressure such as osmotic therapy, glucocorticoids, hyperventilation, barbiturates, and decompressive craniectomy.
Lessons from the TTM trial and planning for the nexstscanFOAM
油
1) Detailed neurological examinations and blinded prognostication were conducted in the TTM trials to minimize bias in outcomes.
2) Follow-up assessments at 6 months in TTM1 found cognitive impairment, depression, and reduced quality of life in about one third of patients despite similar mortality between groups.
3) Extended cognitive testing in TTM1 at 6 months revealed memory, executive function, and processing speed impairments in about half of patients, more than in risk-factor matched controls, showing long-term cognitive consequences after cardiac arrest.
BCC4: Anthony Delaney on Traumatic Brain Injury in the Real WorldSMACC Conference
油
Delaney helps highlight recent research into pre-hospital intubation and intracranial pressure monitoring for patients with TBI. This talk was recorded at Bedside Critical Care Conference 4 and is available with the Intensive Care Network on Libsyn and on www.intensivecarenetwork.com
Guidelines for severe traumatic brain injury4uday kumar
油
This document summarizes guidelines from the Brain Trauma Foundation for the management of severe traumatic brain injury. It defines severe TBI and describes the publication of the 4th edition guidelines in 2016. It provides levels of evidence and recommendations for various treatment topics including decompressive craniectomy, hypothermia, hyperosmolar therapy, cerebrospinal fluid drainage, ventilation therapies, anesthetics/sedatives, steroids, nutrition, infection prophylaxis, deep vein thrombosis prophylaxis, seizure prophylaxis, and intracranial pressure monitoring.
Hot Topics in Critical Care - March 2017Steve Mathieu
油
This document summarizes several recent randomized controlled trials in critical care medicine:
1. A trial comparing high-flow nasal cannula to standard oxygen therapy in patients post-abdominal surgery found no difference in rates of hypoxemia or other outcomes.
2. A trial of intravenous iron in anemic critically ill patients found higher hemoglobin levels at discharge but no difference in transfusion requirements.
3. A trial of dexmedetomidine in elderly surgery patients reduced delirium rates compared to placebo.
PPT on all important trials of traumatic brain injury. - includes design, setting, statistical analysis,outcome, strength, limitations, conclusion#DECRA#RESCUEicp#BEST TRIP#CRASH1#CRASH3#SAFE TBI#EUROTHERM3939#POLAR TRIAL
Also includes trial related BTF guidelines
This document summarizes evidence from multiple clinical trials evaluating the use of thrombolysis/tissue plasminogen activator (tPA) for acute ischemic stroke. It discusses trials showing small benefits for functional outcomes with tPA if given within 3 hours, as well as increased risks of intracranial hemorrhage. Later trials found no clear benefits for tPA between 3-6 hours. Overall, tPA for acute stroke provides only modest benefits for a small proportion of patients, but is also associated with significant risks.
Reperfusion strategy in patients with ST-Segment Elevation Myocardial Infarct...Premier Publishers
油
Reperfusion therapy is the cornerstone in management of STEMI. This study was designed to evaluate both In-hospital and 30 days outcome in patients with STEMI treated with primary percutaneous coronary intervention (PPCI) versus fibrinolysis. This prospective, controlled, study included 140 patients with STEMI who were eligible for reperfusion therapy. In hospital and 30 days major adverse cardiovascular events (MACE) were reported and head to head comparison was done between PPCI versus fibrinolysis. All-cause mortality was reported in 5% of patients (10% versus 0% in fibrinolysis and PPCI respectively, p=0.07), recurrence of ischemic symptoms was reported in 18% of patients (30% versus 7% in fibrinolysis and PPCI respectively, P =0.02), heart failure was evident in 22% of patients (33% versus 10% in fibrinolysis and PPCI respectively, P =0.02). PPCI is safe and effective treatment option for patients with STEMI
Intensive Insulin Therapy In The Medical IcuNadSamm
油
Intensive insulin therapy (IIT) aimed at maintaining tight glycemic control between 4.4-6.1 mmol/L significantly reduced morbidity but not overall in-hospital mortality compared to conventional insulin treatment targeting levels below 10-12 mmol/L in critically ill adult medical ICU patients. Among patients who received at least 3 days of IIT, in-hospital mortality was reduced from 21% to 14% and complications such as newly acquired kidney injury and length of stay were also lower. However, IIT did not reduce mortality in the overall intention-to-treat analysis and may have caused harm in patients treated for less than 3 days. Further research is needed to confirm these preliminary findings.
This randomized controlled trial evaluated whether pre-hospital administration of hypertonic saline or hypertonic saline plus dextran improved 6-month neurological outcomes in patients with severe traumatic brain injury without hypovolaemic shock compared to normal saline. Over 1300 patients were randomized to receive one of the three study fluids. The primary outcome of an extended Glasgow Outcome Scale score of 4 at 6 months was not significantly different between groups. Secondary outcomes including 28-day survival were also not significantly different between groups. The study was terminated early due to futility in showing benefit of the hypertonic fluids over normal saline.
This document provides details about the BOOST3 clinical trial being conducted by the SIREN Clinical Coordinating Center. The trial aims to determine if a treatment protocol informed by brain tissue oxygen (PbtO2) monitoring improves outcomes for patients with severe traumatic brain injury, compared to a protocol using only intracranial pressure monitoring. The Phase 3 trial plans to enroll over 1000 patients at approximately 45 sites. It provides information on the study design, inclusion/exclusion criteria, treatment protocols, and progress to date enrolling sites and investigators.
This randomized controlled trial evaluated the effectiveness of acetyl-L-carnitine (ALC) for treating diabetic neuropathy. Over 1,200 patients with type 1 or 2 diabetes and mild neuropathy were randomized to receive 500 mg or 1,000 mg ALC 3 times daily or placebo for 52 weeks. ALC treatment significantly improved vibration perception threshold and nerve fiber regeneration compared to placebo. Adverse effects were mild and similar between groups. While limited by a short trial period and some baseline differences, ALC appears to be a relatively safe and potentially effective treatment option for mild diabetic neuropathy.
The ALPHEUS trial compared ticagrelor to clopidogrel in reducing periprocedural myocardial injury in 1900 stable coronary patients undergoing high-risk elective PCI. Patients received a loading dose of either ticagrelor 180mg or clopidogrel 300-600mg before PCI, followed by 30 days of maintenance therapy. The primary outcome of periprocedural MI or major myocardial injury within 48 hours did not differ between groups. No differences were found in secondary outcomes including death or MI at 30 days. Ticagrelor did not increase major bleeding but was associated with more minor bleeding and dyspnea. The study concluded that higher platelet inhibition from ticagrelor did not translate to reduced per
Effect Of Remote Ischemic Preconditioning On AKI Among.pptxNayyarSaleem2
油
This document summarizes a randomized controlled trial that evaluated the effect of remote ischemic preconditioning (RIPC) on acute kidney injury (AKI) in patients undergoing cardiac surgery. The study found that among 240 high-risk patients, those who received RIPC had a lower rate of AKI within 72 hours compared to controls. Biomarkers also indicated less kidney damage in the RIPC group. While the study was not powered for secondary outcomes like mortality, RIPC was associated with reduced need for renal replacement therapy. The results provide preliminary evidence that RIPC may help mitigate AKI risk in cardiac surgery patients but larger trials are still needed.
1) The document discusses several major trials related to decompressive craniectomy for traumatic brain injury. The DECRA and RESCUEicp trials investigated the effectiveness of early and late decompressive craniectomy, respectively, and found different outcomes.
2) Controversy remains around how to define "favorable" versus "unfavorable" outcomes. The Eurotherm3235 trial investigated the use of therapeutic hypothermia for TBI but results are still pending.
3) Ongoing trials like RESCUE-ASDH aim to provide more clarity on the optimal surgical management of specific traumatic brain injuries.
2. Objective: to review a recent randomized trial of
intracranial pressure monitoring in sTBI
To encourage thought and discussion of our own
practices
To consider future directions
Nothing for me to disclose
3. Study Overview
Does intracranial pressure monitoring improve
outcomes in severe TBI?
What is the current standard of care in America?
Why does this question matter?
Multicenter, 324 adult pts, severe TBI, randomized
to two separate protocols
Looked at in-hospital events, survival time and 3-
and 6- month outcomes
6. Study Overview
Can we conduct this type of study in America?
Highly unlikely, so let's take advantage of alternative
standards of care to investigate.
Study Design
Multicenter, parallel-group trial
Random assignment to ICP-monitoring group vs imaging-
clinical examination group
Study started in Bolivian hospitals, and additional hospitals
were added later to increase enrollment
7. Study Design Inclusion Criteria
Traumatic brain injury
GCS < 8 on admission or within first 48 hours after
injury (Motor score 5 if intubated)
Admission to study hospital within 24 hours of injury
No foreign object in the brain parenchyma.
Age > 12
Randomized:
within 24 hours of injury [for patients with GCS < 8 on admission] or
within 24 hours of deterioration [patients deteriorating to GCS < 8
within 48 hours of injury
Randomization stratified according to site, injury
severity score, and age
8. Study Design Exclusion Criteria
GCS of 3 with bilateral fixed and dilated pupils
No consent
Pregnant
Prisoner
No beds available in ICU
No ICP monitor available
Non-survivable injury
Other (e.g., Pre-injury life expectancy under 1 year)
Pre-existing neurological disability that would
confound outcome
9. Study Design - protocol
Place patient on mechanical ventilation (VM)
Place continuous SaPO2 and EtCO2 monitors
Insert indwelling urinary catheter to monitor urine output
Insert arterial catheter for arterial mean pressure monitoring
Insert central venous catheter for infusion of solutions and
central venous pressure monitoring.
Monitor neurological clinical status each hour
Pupils
GCS
Brain CT
To evaluate evolution 48 hours after the admission CT
To evaluate evolution 5-7 days after the admission CT
p.r.n.
10. Study Design Standards of Critical Care
Clearly delineate standard basic Critical Care
Head positioning 30尊
Head and neck in neutral position and aligned
Avoid hyperthermia (Defined as central temperature > 38 尊 C)
Non-drug measures (cooling)
Dipirona (Metamizole sodium)
Early enteral nutritional support
Before 48 hours
25 Kcal/kg weight
Pharmacologic prophylactic of post traumatic seizures (Phenytoin (IV or PO))
Load and maintenance dose as is being giving in each hospital
Gastric bleeding prophylaxis
Ranitidine or Omeprazol
Avoid decubitus lesions
Deep venous thrombosis prophylaxis
Frequent tracheal suctioning with sterile technique to prevent pulmonary infections
11. Study Design ICP group
Had parenchymal monitor ASAP (i.e. after
randomization and resolution of coagulopathy if
present)
Position was not specified
Treat if ICP20mmHg x 5min
If CSF drainage indicated, EVD placed
CPP goal 50-70mmHg
12. Study Design Treatments (ICP Group)
Treatments based on a Therapeutic Intensity Level
If signs of intracranial HTN, clinical or imaging
1 hyperosmolar therapy (mannitol)
5% NaCl only if hypotenisve, hypovolemic, hyponatremic
2 optional mild hyperventilation (pCO2 30-35mmHg)
3 Ventricular drainage if possible*
13. Study Design Definitions (ICP Group)
Intracranial Pressure Definitions:
Treatable intracranial hypertension:
ICP > 20 mmHg for > 5 minutes
Treatment failure:
ICP not reduced to 20 mmHg within 20 minutes after a
treatment intervention is initiated, and
Persistent elevation in ICP > 20 mmHg requires increase in
therapeutic intensity level
14. Study Design Neuroworsening
Neuroworsening = Incd TIL
1. Decrease in the motor GCS > 2
2. New loss of pupil reactivity
3. Interval development of pupil asymmetry of > 2mm
4. New focal motor deficit
5. Herniation syndrome
Give mannitol 0.25-1mg/kg to sOSM<320
Hyperventilate to pCO2 25-30
If no response thiopental x 3d
Craniectomy for space-occupying lesions
15. Study Design Imaging only Group
After optimized sedation and analgesia,
hyperventilation and hyperosmotic therapy
should be started simultaneously if there is
evidence of edema on CT, as indicated as
following:
1. Compressed peri-mesencephalic cisterns
2. Midline shift
3. Cortical sulcal compression / effacement
Otherwise, same metrics and goals of ICP
monitored group
Corticosteriods prohibited
AEDs for prophylaxis >28d
16. Study Design - Outcomes
Primary outcome 21-point composite of survival,
duration and level of impaired consciousness, 3-
month GOSe and GOAT, 6-month GOSe and
neuropsych testing
Secondary Outcomes ICU LOS, number of days
that patients received at least 1 brain-specific
treatment, days of MV, treatment with high-dose
barbiturates, decompressive crani
19. Results
MVAs accounted for most injuries (51% of
randomized pts)
45% of pts were brought in by ambulance
Remainder were transferred from other facilities
Did not publish pre-hospital demographics or
interventions as these we not uniformly recorded
20. Results - Demographics
24% of randomized patients had clinical decline to
GCS within eligibility criteria
49% of patients had localizing signs on clinical exam
33% of participants required surgical treatment of
mass lesions
On initial CT, 85% had cisternal compression and
36% had >5mm midline shift
22. HR for death at 6mos =1.10,
slightly in favor of ICP group
25. Results Subgroup Analysis
Hospital LOS was slightly shorter in the ICE group (iqr 12 for
ICP, 9 for ICE)
No significant differences in MV days, of non-neurologic
complications
Except ICP-monitored pts had a higher incidence of decubitus ulcers
(12%vs 5%, P=0.03)
Median time of ICP monitoring was 3.6d
Incidence of Neuroworsening after randomization was 25% in
the entire study, and was similar in both groups
Median interval for brain-specific treatments was longer in
ICE group
Use of barbiturates was significantly higher in the ICP group
(24% vs 13%)
HTS and HV were used more in the ICE group (72% vs 58%,
73% vs 60%)
26. Results
Almost every variable, including LOS, mortality, anf
functional outcomes favored ICP monitoring with a
HR>1.
The study was powered to detect statistical
significance of HR>1.5
Subgroup analysis of HR accounting for Marshall CT
Classification
27. Results Summary
Composite endpoints between the two groups were
similar (P=0.49)
ICP group = 56
ICE group = 53
Mortality at 6 months (P=0.06)
ICP group=39%
ICE group=41%
ICE group had more days of brain specific
treatments (hyperosmolar therapy, HV)
28. Discussion
So what did the trial show?
Clinicians act on ICP, without clinical correlate as
evidenced by the increased use of barbiturates
Clinicians also act on clinical findings without
quantitative evidence of intracranial hypertension as
evidenced by more brain-specific treatments overall
in the ICE group.
Is this because increased ICP could herald clinical
changes and early interventions abort herniation
events?
Also, radiographic signs may not translate to the
parenchymal monitor.
29. Discussion - Skepticism
South America differences in pre-hospital, and post-
hospital care
Less might survive to hospital or to hospital transfer
Rehabilitation standards are different and may not
translate to the same cognitive recovery
35%death in all groups after 14d
Adjusted estimates of sTBI mortality in the US varies
from 41%-25% (J Neurotrauma. 2012 Jan 1;29(1):47-52., J Neurotrauma. 2012 Jan
1;29(1):47-52.)
The Thereapeutic Intensity Level is a good overall
metric but others such as %responders to ICP-lowering
therapy has proven predictive and should have been
incorporated (J Neurosurg. 2011 May;114(5):1471-8)
30. Discussion - Skepticism
Technology parenchymal monitors as standard
Triggers for treatment? ICP>20 x 5 min vs
radiographic signs with or without clinical correlates
ICP group ICP triggers ICP is too simplistic a
reflection of intracranial pathophysiology. No
account for CPP
Clinical signs dont always reflect global pressures
and vice versa
No discussion of inclusion/exclusion of polytrauma
and surgical interventions
31. Discussion - Skepticism
Variability in treatments (i.e. more mannitol and HV
in the ICE group) may be because the ICE group had
scheduled scans and interventions and the ICP group
had more event-related treatment triggers
Conversely, that may explain why the ICP group had
more barbiturates and HTS
32. Discussion - benefits
Very rigorous treatment algorithm for management
of elevated ICP (either qualitative or quantitative)
Homogenous population across countries
Both groups had intracranial HTN treated that
isnt in question
In truth, this study did not test ICP monitoring, only
a very specific treatment algorithm to an ICP
threshold compared with clinical exam
In the end, the neurologic exam might STILL be the
best tool in our disposal.
33. Further Discussion
This was probably the only way that this type of trial
could be done
Authors were careful not to compare South American
patients to our own, only report their findings
The goal of therapies was to lower the average ICP
within the head this doesnt accurately reflect
mechanical compression and injury to diepnephalic
which may portend a worse prognosis. The clinical
signs of elevated ICP (pupil dilations, posturing,
coma) are directly related to these areas.
34. Further Discussion
How would you alter the study?
Could multimodal monitoring be the next step?
Are composite endpoints more useful that single
variable? i.e. mortality? Return to work?
Is a 6-month outcome long enough?
Dont forget that even the most rigorous study
cannot account for all possible variables and that this
data might not apply to every patient.
Editor's Notes
#19: No significant differences between the groupsOnly true subjective variable is the signs of intracranial hypertension, which is recorded as the impression as the interpreting physician